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ABSTRACT
Objectives: The aim of the study was to assess the effectiveness of postmenopausal osteoporosis treatment with natural 
sex hormones. 
Material and methods: The single-blind study included 210 women, randomly allocated to three different groups, with 
various methods of treatment: Group I (70 controls) received transcutaneous placebo for the course of one year, Group 
II (70 females, aged 52.2 ± 3.1 years) used oral hormone supplementary therapy (HST), and Group III (70 females, aged 
51.9 ± 3.5 years) received transcutaneous modified hormone replacement therapy (MHRT), supplemented with intravaginal 
lutein, dietary minerals, and 1000 IU of vitamin D3/day. 
Results: No increase in bone mineral density was observed in the control group. However, mineral density of the vertebral 
bodies was significantly higher after 3 and 5 years in the HST group (p < 0.05), and after 1 year in the MHRT group (p < 0.01). 
This increase was even more significant (p < 0.001) after 3 and 5 years in the MHRT group. 
Conclusions: Transcutaneous hormone therapy with micronized estradiol and progesterone is the treatment of choice in 
postmenopausal osteoporosis, as evidenced by bone mineral density and biochemical markers.
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INTRODUCTION
Postmenopausal osteoporosis belongs to the group 
of primary involutional pathologies and is responsible for 
as many as 80% of the cases of metabolic bone disease. Its 
etiology has been linked with estrogen deficit [1–5], and 
dysfunction of the thyroid gland [6–10], adrenals [11, 12], 
or the hypothalamic-pituitary axis [13–17]. Estrogens play 
a key role in maintaining bone mass and stabilizing bone 
metabolism through inhibition of the resorptive activity 
of osteoclasts and stimulation of osteogenesis by osteo-
blasts. Osteoblasts suppress the secretion of resorptive cyto-
kines IL-1, IL-6, and TNF-α, which act as paracrine regulators 
of osteoblasts. Since the 1960s, estrogens have been used 
to treat osteoporosis owing to their enhancement of the 
expression of vitamin D3 receptors, growth hormone recep-
tors, and the osteoprotegerin gene [18], and their regulatory 
action on the thyroid gland [19]. Estrogens, like testosterone, 
stimulate bone metabolism [20]. Moreover, estrogens pro-
mote the uptake of microelements in the gastrointestinal 
system, thus maintaining a positive metabolic balance in the 
bones [21]. Estrogen action depends on their type, dose, and 
route of administration. The oral route is commonly used, 
although it is associated with adverse effects in the form of 
arterial hypertension, stroke, myocardial infarction, as well 
as tumors of the uterus, ovaries and glands of the mucous 
membranes. These adverse effects were the reason behind 
the decision to administer a modified hormone therapy with 
a 50% smaller dose of estrogens as compared to the dose 
recommended by the manufacturer.
OBJECTIVE
The study was undertaken to assess the effects of oral 
hormone supplementary therapy (HST) and transcutane-
ous modified hormone replacement therapy (MHRT) on 
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biochemical and clinical aspects of postmenopausal osteo-
porosis, using the following parameters: concentrations of 
gonadotropins, estrogens, progesterone, prolactin, markers 
of bone turnover (bone-specific alkaline phosphatase, pro-
collagen, osteocalcin), insulin-like growth factor, and growth 
hormone, as well as the mineral densities of L1–L4 vertebral 
bodies, body mass index, and arterial blood pressure. 
MATERIAL AND METHODS
Our single-blind, placebo-controlled study enrolled 
210 female city dwellers without a history of chronic ill-
ness or hereditary disease. Group I comprised 70 women 
who received placebo (Janssen-Cilag Baar, Switzerland) 
in the form of transcutaneous plasters administered over 
the course of one year. Group II included 70 women (aged 
52 ± 3.1 years) who received oral HST with Cyclo-Menorette 
(Wyeth-Munster), containing 1 mg estradiol with a molecular 
weight of 343.39 g, 2 mg estradiol with a molecular weight of 
288.38 g, and 0.25 mg levonorgestrel with a molecular weight 
of 312.4 g, with therapeutic cycles of 22 days, followed by 
a treatment-free interval of 7 days to induce menstruation. 
Group III included 70 women (aged 51.9 ± 3.5 years) who 
received transcutaneous modified HRT (MHRT) developed by 
Stanosz [22] and based on Systen 50 (Janssen-Cilag Baar, Swit-
zerland), containing 17β-estradiol with a molecular weight 
of 272.39 g, supplemented from day 11 with micronized 
lutein (molecular weight: 314.47 g) from Adamed Pienkow 
(Poland). The dose of lutein was 50 mg/24h for the first and 
100 mg/24h for the next 6 days. Therapeutic cycles of 22 days 
were followed by a treatment-free interval of seven days to 
induce menstruation. All participants followed a mineral-rich 
diet and received 1000 IU/24 h of vitamin D3 (Vitrum) during 
the autumn-spring season. Bromocriptine (5 mg/24 h) was 
administered for 12 days in women with hyperprolactinemia. 
Oral Metformax (850 mg/24 h; Teva) was administered for 
12 days to women with hyperinsulinism. Venous blood was 
collected in the morning. Concentrations of gonadotropins, 
estrogens, progesterone, prolactin, growth hormone, os-
teocalcin, procollagen, and insulin-like growth factor were 
determined with Elisa (IBL). Alkaline phosphatase activities 
were measured with test kits from DRG. Bone mineral density 
(BMD) of the lumbar vertebral bodies was determined with 
the DEXA DPX-TQ densitometer from Lunar Corporation. As-
sessment of bone density was done according to the WHO 
recommendations. Clinical and sonographic (Siemens Adara, 
USA) examinations of the breasts, ovaries, and the endome-
trium were performed during a 5-year follow-up. Local Ethics 
Committee approved of the study (№ BN-001/05).
Statistical analyses
Statistical analyses were performed using Statistica 9. Dis-
tributions of serum concentrations for most hormones devi-
ated significantly from the norm, as determined with the 
Shapiro-Wilk test, in which case nonparametric tests were 
applied. The significance of change in hormone concentra-
tion during follow-up was assessed with Friedman’s ANOVA 
and the Wilcoxon matched-pairs test. The significance of the 
differences between the groups was determined with the 
Kruskal-Wallis ANOVA test and the Mann-Whitney U-test. 
The significance of change in BMD during follow-up was 
evaluated with Student’s paired samples t-test in each group 
of patients. The significance of differences in BMD between 
the three groups of patients was assessed with ANOVA and 
Tukey’s post-hoc test. Statistical significance in the case of per-
centage values was determined with the chi-square test. The 
p-value of < 0.05 was considered as statistically significant. 
RESULTS
The results are shown in Tables 1–7. Table 1 demon-
strates that the participants were homogenous as to age, 
body weight, parity, residence, and age at menopause; no 
statistically significant differences were found.
Table 2 contains mean values and standard deviations 
for all parameters in the group of patients on placebo at 
the start and after one year of follow-up. BMD of L3 and 
L4 vertebral bodies was significantly lower after one year 
of placebo (p < 0.05). 
Table 3 shows the results in groups II and III before treat-
ment; no significant differences were noted. After one year 
of HST and MHRT (Table 4), the concentrations of gon-
adotropins (FSH, LH) decreased significantly (p < 0.001), 
while the concentrations of estrogens increased signifi-
cantly (p < 0.001). HST patients demonstrated significantly 
higher concentrations of prolactin, body mass index, and 
systolic blood pressure (p < 0.05). In this group, concentra-
tions of bone-forming factors were insignificantly reduced. 
Patients on MHRT presented with higher concentrations of 
the growth hormone, progesterone, IGF-1, and activities of 
the bone-specific alkaline phosphatase (p < 0.05). 
Table 5 demonstrates that the concentrations of gon-
adotropins (FSH, LH) and estrogens after three years of oral 
HST and transcutaneous MHRT were significantly lower 
(p < 0.001) and significantly higher (p < 0.001), respectively. 
HST patients presented with significantly higher concentra-
tions of prolactin (p < 0.01), growth hormone (p < 0.01), and 
BMI (p < 0.01). In this group, significantly reduced concentra-
tions of IGF-1 (p < 0.01) and bone-forming factors (p < 0.05) 
were noted. MHRT patients demonstrated elevated concen-
trations of progesterone, IGF-1, and procollagen (p < 0.05). 
Activities of the bone-specific alkaline phosphatase were 
reduced (p < 0.01). No significant differences in BMI and 
arterial blood pressure values were found. 
Table 6 shows that five years of oral HST and transcuta-
neous MHRT produced significantly lower concentrations 
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of gonadotropins (FSH, LH) (p < 0.001) and significantly 
higher concentrations of estrogens (p < 0.001). In case of HST 
patients, bone-forming factors (bALP, PICP, OC) decreased 
significantly (p < 0.05). Concentrations of IGF-1 were signifi-
cantly lower as well (p < 0.01). Significantly higher concen-
trations of the growth hormone, BMI, and blood pressure 
values were observed (p < 0.01). MHRT patients presented 
with significantly higher concentrations of progesterone 
(p < 0.01), osteocalcin (p < 0.01), IGF-1, growth hormone 
(p < 0.001), and procollagen (p < 0.01). BMI increased sig-
nificantly (p < 0.05) and no change in arterial blood pressure 
values was found. 
Table 7 demonstrates that one year of placebo resulted 
in significant reductions in BMD of L1–L4 vertebral bodies 
(p < 0.05), as well as in the respective percentage values 
(p < 0.05). In group II, L1–L4 BMD values were greater after 
one year (p < 0.05), without a tendency to higher values after 
three and five years of the follow-up. Patients using trans-
cutaneous MHRT presented with greater BMD of L1–L4 ver-
tebral bodies after one year (p < 0.05) and higher values 
after three (p < 0.01) and five years of follow-up (p < 0.001). 
DISCUSSION
The present study has shown that the type of estrogen 
and the route of administration both exert an influence 
on hormone metabolism and therapy outcome. Signifi-
cantly reduced concentrations of FSH and LH (p < 0.001) are 
linked with the route of administration [23, 24]. Hormone 
distribution is important in case of estrone and estradiol 
[25]. Oral estrogens in group II (HST) are partially (70%) 
metabolized by the liver, excreted with the bile together 
with other metabolites, and taken up again in the small 
intestine [26]. Oral hormone therapy is associated with he-
patic conversion of estradiol to estrone and its conjugates 
with glucuronic and sulfuric acids [27]. Multiple passages of 
estrogens through the liver lead to an additive effect during 
subsequent therapeutic cycles [28]. Acting on hepatocytes, 
estrogens stimulate the synthesis of hormone-transporting 
proteins, thus reducing the fraction of free hormones and 
their tissue availability. Transcutaneous MHRT in group III 
Table 1. Clinical data of women receiving placebo (group I), oral HST (group II), and transcutaneous modified MHRT (group III)  
(mean ± standard deviation)
Parameters Group I (placebo) n = 70
Group II (HST)
n = 70
Group III (MHRT)
n = 70 p
#
Age 50.8 ± 3.4 52.1 ± 3.1 59.9 ± 3.5 NS
BMI 24.7 ± 3.9 24.2 ± 1.1 23.8 ± 1.2 NS
Systolic blood pressure [mm Hg] 120.5 ± 22.1 127.28 ± 13.24 126.52 ± 16.55 NS
Diastolic blood pressure [mm Hg] 74.9 ± 6.1 75 ± 9.4 93 ± 11.7 NS
Parity 2.4 ± 0.9 2.1 ± 0.7 1.9 ± 0.9 NS
Number of abortions 1.5 ± 0.85 1.7 ± 0.2 1.4 ± 1.9 NS
Age at menopause (yrs) 49.1 ± 1.6 49.7 ± 2.3 49.3 ± 1.9 NS
Postmenopausal age (yrs) 3.9 ± 1.4 3.5 ± 1.8 3.4 ± 2.1 NS
Smokers (%) 17.9 18.7 20.5 NS
mm Hg = 0.1333 kPa 
Group I — transcutaneous placebo; Group II — oral HST; Group III — transcutaneous MHRT; NS — not significant; n — number of women in the group; p — level of 
significance; #Mann-Whitney U test or chi-square test
Table 2. Concentrations of gonadotropins (FSH, LH), estrogens 
(E1, E2), progesterone (P), prolactin (PRL), bone-specific alkaline 
phosphatase (bALP), procollagen (PICP), osteocalcin (OC), growth 
hormone (GH), insulin-like growth factor (IGF-1), body mass index 
(BMI), systolic and diastolic blood pressures in group I (placebo)
Markers
Group I n=70
Placebo (before 
treatment)
Group I n=70
Placebo (after 
treatment)
FSH [mIU/mL] 69.1 ± 8.4 72 ± 11
LH [mIU/mL] 37.3 ± 11.0 35.0 ± 9.7
E1 [pg/mL] 22.1 ± 3.1 20.1 ± 1.5
E2 [pg/mL] 19.71 ± 7.2 17.3 ± 4.3
P [ng/mL] 0.21 ± 0.7 0.2 ± 0.03
PRL [ng/mL] 18.7 ± 2.4 23.3 ± 4.1*
bALP [ng/mL] 31.7 ± 4.2 30.1 ± 3.2
PICP [ng/mL] 133.0 ± 22.0 135.0 ± 19.7
BGP [ng/mL] 18.4 ± 3.1 17.9 ± 3.2
IGF-1 [ug/L] 97.4 ± 11.3 94.1 ± 3.7
GH [mIU/L] 1.5 ± 0.7 1.3 ± 0.4
BMI [kg/m2] 25.9 ± 3.1 23.8 ± 4.1
Systolic blood 
pressure [mm Hg] 124.1 ± 9.7 135 ± 6.2*
Diastolic blood 
pressure [mm Hg] 71.1 ± 6.2 75.0 ± 4.1
mm Hg = 0.1333 kPa 
n — number of women; p — level of significance; *p < 0.05, Wilcoxon 
matched-pairs test
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Table 3. Concentrations of gonadotropins (FSH, LH), estrogens (E1, E2), progesterone (P), prolactin (PRL), bone-specific alkaline phosphatase 
(bALP), procollagen (PICP), osteocalcin (OC), growth hormone (GH), insulin-like growth factor (IGF-1), body mass index (BMI), systolic and diastolic 
blood pressures in group II (HST) and group III (MHRT) before treatment
Markers Group II (HST) n = 70 Group III (MHRT) n = 70 p
FSH [mIU/mL] 72.1 ± 17 65.4 ± 11.3 NS
LH [mIU/mL] 35.2 ± 12 33.5 ± 12.2 NS
E1 [pg/mL] 20.5 ± 2.81 14.31 ± 4.49 NS
E2 [pg/mL] 18.54 ± 2.84 20.89 ± 2.16 NS
P [ng/mL] 0.27 ± 0.9 0.29 ± 0.11 NS
PRL [ng/mL] 12.64 ± 2.95 11.44 ± 2.13 NS
bALP [ng/mL] 29.1 ± 5.3 30.2 ± 4.7 NS
PICP [ng/mL] 134.7 ± 22.1 124.4 ± 31.7 NS
BGP [ng/mL] 17.6 ± 5.3 15.3 ± 4.4 NS
IGF-1 [ug/L] 98.2 ± 30.7 99.2 ± 29.2 NS 
GH [mIU/L] 1.1 ± 0.4 1.3 ± 0.9 NS
BMI [kg/m2] 24.2 ± 0.9 23.9 ±1.4 NS
Systolic blood pressure [mm Hg] 127.28 ± 13.24 126.52 ± 16.55 NS 
Diastolic blood pressure [mm Hg] 80.42 ± 7.21 76.5 ± 7.55 NS
mm Hg = 0.1333 kPa  
n — number of women in the group; NS — not significant; p — level of significance, Mann-Whitney U-test
Table 4. Concentrations of gonadotropins (FSH, LH), estrogens 
(E1, E2), progesterone (P), prolactin (PRL), bone-specific alkaline 
phosphatase (bALP), procollagen (PICP), osteocalcin (OC), growth 
hormone (GH), insulin-like growth factor (IGF-1), body mass index 
(BMI), systolic and diastolic blood pressures in group II (HST) and 
group III (MHRT) after one year of treatment
Markers Group II (HST) n = 70
Group III (MHRT) 
n = 70
FSH [mIU/mL] 52.1 ± 12.3**** 45.4 ± 12.3***
LH [mIU/mL] 25.6 ± 11.6**** 27.1 ± 10.1***
E1 [pg/mL] 226.6 ± 50.3**** 209.6 ± 6.6***
E2 [pg/mL] 127.2 ± 27.9**** 182.7 ± 17.7***
P [ng/mL] 0.21 ± 0.7 4.18 ± 0.22***
PRL [ng/mL] 16.15 ± 3.51* 12.41 ± 2.15
bALP [ng/mL] 25.3 ± 14.7 33.7 ± 6.1* 
PICP [ng/mL] 131.3 ± 19.3 127.3 ± 29.3
BGP [ng/mL] 15.1 ± 6.2 19.4 ± 6.7*
IGF-1 [ug/L] 90.8 ± 17.4 118 ± 31.1**
GH [mIU/L] 1.4 ± 0.9* 2.5 ± 1.9**
BMI [kg/m2] 25.7 ± 1.4 24.5 ± 1.1
Systolic blood 
pressure [mm Hg] 137.42 ± 8.85* 128.38 ± 8.07
Diastolic blood 
pressure [mm Hg] 87.57 ± 5.9* 77.57 ± 4.43
mm Hg = 0.1333 kPa  
n — number of women in the group; p — level of significance; *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001 in comparison to initial values
Table 5. Concentrations of gonadotropins (FSH, LH), estrogens 
(E1, E2), progesterone (P), prolactin (PRL), bone-specific alkaline 
phosphatase (bALP), procollagen (PICP), osteocalcin (OC), growth 
hormone (GH), insulin-like growth factor (IGF-1), body mass index 
(BMI), systolic and diastolic blood pressures in group II (HST) and 
group III (MHRT) after three years of treatment
Markers Group II (HST) n = 70
Group III (MHRT) 
n = 70
FSH [mIU/mL] 27.3 ± 7.1**** 24.6 ± 11.2***
LH [mIU/mL] 16.4 ± 7.4**** 12.4 ± 8.4***
E1 [pg/mL] 209.58 ± 10.8**** 70.66 ± 12.23****
E2 [pg/mL] 122.77 ± 16.66**** 63.5 ± 10.11***
P [ng/mL] 0.2 ± 0.06 4.49 ± 0.31***
PRL [ng/mL] 20.81 ± 4.13** 12.1 ± 1.8
bALP [ng/mL] 21.2 ± 6.1 37.1 ± 8.1**
PICP [ng/mL] 130.1 ± 33.1 130.8* ± 27.2
BGP [ng/mL] 14.1 ± 4.9 29.4 ± 6.1
IGF-1 [ug/L] 84.0 ± 20.3* 128.7 ± 30.0*** 
GH [mIU/L] 2.1 ± 1.8** 3.4 ± 2.1***
BMI [kg/m2] 27.2 ± 1.8** 25.3 ± 1.2 
Systolic blood 
pressure [mm Hg] 137.92 ± 8.85* 126.38 ± 8.7
Diastolic blood 
pressure [mm Hg] 84.57 ± 5.98 77.57 ± 4.43
mm Hg = 0.1333 kPa 
n — number of women in the group; p — level of significance; *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001 in comparison to initial values
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Table 6. Concentrations of gonadotropins (FSH, LH), estrogens 
(E1, E2), progesterone (P), prolactin (PRL), bone-specific alkaline 
phosphatase (bALP), procollagen (PICP), osteocalcin (OC), growth 
hormone (GH), insulin-like growth factor (IGF-1), body mass index 
(BMI), systolic and diastolic blood pressures in group II (HST) and 
group III (MHRT) after five years of treatment
Markers Group II (HST) n = 70
Group III (MHRT) 
n = 70
FSH [mIU/mL] 23.3 ± 8.1**** 21.3 ± 8.4****
LH [mIU/mL] 19.5 ± 0.1**** 18.5 ± 5.3****
E1 [pg/mL]] 210.1 ±11.4**** 78.3 ± 8.4***
E2 [pg/mL] 123.1 ± 14.1**** 72.4 ± 9.7****
P [ng/mL] 0.11 ± 0.05 4.3 ± 0.51****
PRL [ng/mL] 21.3 ± 5.1** 12.9 ± 1.6
bALP [ng/mL] 20.8 ± 6.4** 35.0 ± 6.1*
PICP [ng/mL] 125.8 ± 11.7* 140.5 ± 21.3**
BGP [ng/mL] 18.1 ± 6.9* 25.5 ± 5.9**
IGF-1 [ug/L] 93.1 ± 14.1** 131.5 ± 11.3***
GH [mIU/L] 2.9 ± 1.4** 3.8 ± 2.2***
BMI [kg/m2] 28.9 ± 1.2* 24.9 ± 1.3
Systolic blood 
pressure [mm Hg] 138.28 ± 5.8** 128.38 ± 7.42
Diastolic blood 
pressure [mm Hg] 88.0 ± 4.05 82.3 ± 3.67
mm Hg = 0.1333 kPa 
n — number of women in the group; p — level of significance; *p<0.05; 
**p<0.01; ***p < 0.001; ****p < 0.0001 in comparison to initial values
Table 7. Mineral densities of L1-L4 vertebral bodies depending on the method of treatment
Group n Examination L1 [g/cm2]
L2
[g/cm2]
L3
[g/cm2]
L4
[g/cm2]
BMI % 
L1–L4
I
Placebo 70
Initial 0.883 ± 0.091 0.935 ± 0.077 0.917 ± 0.065 0.955 ± 0.071 –
After one year 0.868 ± 0.051 0.900 ± 0.066 0.880 ± 0.052 0.910 ± 0.046 –3.53
II
HST 70
Initial 0.883 ± 0.091 0.935 ± 0.087 0.917 ± 0.065 0.952 ± 0.071 –
After one year 0.908 ± 0.071 0.956  ± 0.081 0.959* ± 0.056 0.952* ± 0.067 +4.38
After three years 0.917* ± 0.071 0.975* ± 0.062 0.967* ± 0.060 0.991* ± 0.083 +3.98
After five years 0.92* ± 0.067 0.963* ± 0.074 0.957* ± 0.068 0.992* ± 0.091 +4.15
III
MHRT 70
Initial 0.872 ± 0.066 0.921 ± 0.059 0.957 ± 0.41 0.942 ± 0.071 –
After one year 0.902* ± 0.086 0.954* ± 0.091 0.971* ± 0.067 0.947* ± 0.061 +4.4
After three years 0.997** ± 0.071 1.094*** ± 0.084 1.021*** ± 0.066 1.019*** +7.4
After five years 1.011*** ± 0.088 1.019*** ± 0.091 1.013*** ± 0.076 1.016*** ± 0.081 +10.83
n — number of women in the group; p — level of significance; *p < 0.05; **p < 0.01; ***p < 0.001 in comparison to initial values
precluded the primary passage through the portal system 
of the liver, resulting in serum concentrations of estrogens 
which are sufficient to alleviate menopausal symptoms and 
improve bone metabolism. MRHT women presented with 
a three-fold increase in the concentrations of estrogen and 
a normal E1:E2 ratio (1:1). The concentration curve resem-
bled a sinusoid, as in physiologic menstrual cycles. Serum 
concentration of progesterone increased five-fold and pro-
vided for optimal secretory activity of the endometrium 
during the second phase of the therapeutic cycle. Synthesis 
of the insulin-like growth factor is induced in osteoblasts 
by estrogen and the growth hormone [29], stimulating the 
precursor of osteoclasts and bone formation [30, 31]. The 
liver is the main source of circulating IGF-1 [32, 33]. 
Numerous studies have confirmed that the effect of es-
trogens on the concentration of GH, IGF-1, and bone-form-
ing factors depends on the route of administration. Sig-
nificantly higher concentrations of estrone and estradiol in 
women using oral HST are linked with the chemical structure 
and distribution. The effect of estrogens on the liver is due 
to two mechanisms of turnover of the inactive substrate 
to the active hormone, and is associated with the binding 
to hepatocyte receptors, leading to stimulation of protein 
synthesis and modulation of biochemical processes. It has 
frequently been noted that oral estrogens produce an effect 
on lipid metabolism, as well as on the synthesis of renin, 
blood-clotting factors, and the sex hormone-binding globu-
lin (SHBG). Enhanced synthesis of SHBG is associated with 
reduced concentrations of free estradiol acting on tissue 
receptors. In turn, impaired availability produces signifi-
cantly smaller concentrations of the bone-specific alkaline 
phosphatase, osteocalcin, procollagen, IGF-1, as well as 
BMD values seen after one, three, and five years of HST. 
Transcutaneous MHRT provided for optimal mean concen-
trations of E1 and E2, which fully prevented bone mass loss 
as confirmed with densitometry. Even though the dose of 
estrogens in MHRT has been reduced by 50 %, menopausal 
symptoms and metabolic disorders could still be alleviated. 
One year of balanced transcutaneous hormone therapy 
(MHRT) has stabilized concentrations of bone-forming fac-
tors, thus producing significantly higher BMD, as well as 
maintaining arterial blood pressure and BMI values seen 
744
Ginekologia Polska 2016, vol. 87, no. 11
www. journals.viamedica.pl/ginekologia_polska
after one, three, and five years of treatment. Five years of 
HST have been associated with hyperprolactinemia in 25%, 
arterial hypertension in 11%, elevated serotonin concentra-
tion in 11.5%, mammary cysts in 9.8%, mammary fibrocystic 
lesions in 11.3%, and benign endometrial hyperplasia in 
9.7% of the cases. In contrast, mammary cysts were seen in 
just 2.3% of women receiving transcutaneous MHRT.
CONCLUSIONS
Transcutaneous hormone therapy with micronized 
estradiol and progesterone is the procedure of choice in 
postmenopausal osteoporosis.
Transcutaneous hormone therapy with micronized es-
tradiol and progesterone in rising doses, with a seven-day 
interval between therapeutic cycles, provides for a physi-
ologic rhythm in estrogen and progesterone concentrations, 
with sinusoidal concentration curves resembling those dur-
ing normal menstrual cycles. 
Significantly lower concentrations of biochemical mark-
ers and mineral density values in L1–L4 vertebral bodies of 
women using oral supplementary therapy with synthetic 
hormones may be attributed to chemical structure, me-
tabolism, and hyperprolactinemia. 
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